Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Obermüller, N; Rosenkranz, AR; Müller, HW; Hidde, D; Veres, A; Decker-Burgard, S; Weisz, I; Geiger, H.
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study).
Int J Mol Sci. 2017; 18(10):
Doi: 10.3390/ijms18102057
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Rosenkranz Alexander
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis patients and 119 predialysis patients. In predialysis patients, median intact parathormone (iPTH) was 180.0 pg/mL (n = 105) at the start of the study, 115.7 pg/mL (n = 105) at last documentation, and 151.8 pg/mL (n = 50) at month 12, with 32.4% of the last documented iPTH values in the KDOQI (Kidney Disease Outcomes Quality Initiative) target range. In dialysis patients, median iPTH was 425.5 pg/mL (n = 569) at study start, 262.3 pg/mL (n = 569) at last documentation, and 266.1 pg/mL (n = 318) at month 12, with 36.5% of dialysis patients in the KDOQI target range. Intravenous paricalcitol showed more homogenous iPTH control than oral treatment. Combined analysis of all dialysis patients indicated comparable and stable mean serum calcium and phosphate levels throughout the study. Clinical symptoms, such as itching, bone pain, and fatigue, were improved compared with study entry. The spectrum and frequency of adverse events mirrored the known pattern for patients on dialysis. Paricalcitol is efficacious and has a consistent safety profile in sHPT over 12 months.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Austria -
- Biomarkers -
- Bone Density Conservation Agents - therapeutic use
- Calcium - blood
- Ergocalciferols - therapeutic use
- Female -
- Germany -
- Humans -
- Hyperparathyroidism, Secondary - drug therapy
- Hyperparathyroidism, Secondary - etiology
- Kidney Failure, Chronic - complications
- Kidney Failure, Chronic - diagnosis
- Kidney Failure, Chronic - drug therapy
- Kidney Function Tests -
- Male -
- Middle Aged -
- Phosphorus - blood
- Renal Dialysis - adverse effects
- Renal Dialysis - methods
- Renal Insufficiency, Chronic - complications
- Renal Insufficiency, Chronic - diagnosis
- Renal Insufficiency, Chronic - drug therapy
- Renal Insufficiency, Chronic - etiology
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- parathormone (PTH)
- paricalcitol
- secondary hyperparathyroidism (sHPT)
- chronic kidney disease (CKD)
- dialysis
- predialysis